[1] In the majority of cases, it leads to patients and families traveling abroad to obtain procedures that are not proven, nor part of a clinical trial approved by an authority like the Food and Drug Administration in the United States.
[3] Although for the general public, this advertising in glossy websites, may sound authoritative, for translational doctors and scientists this leads to the exploitation of vulnerable patients.
[4] These activities are highly profitable for the clinic but no benefit for the patients, sometimes experiencing complications like spinal tumors,[5] death, or financial ruin, all of which are documented in the scientific literature.
One of the key elements in the RTT is the concept of promising, that is not just a theoretical possibility but a demonstrable and reproducible evidence obtained by scientific experimentation.
[14] The right to try legislation seek opportunities for incurables and often terminal patients to receive the compassionate use of experimental therapies that have passed phase I clinical trials that have not gone through all the checks and balances needed for approval.